Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Salarius Pharmaceuticals, Inc. SLRX
$1.36
-$0.04 (-2.64%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
3530556.00000000
-
week52high
7.20
-
week52low
1.07
-
Revenue
0
-
P/E TTM
0
-
Beta
1.12403800
-
EPS
-14.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 11 мар 2022 г. |
| HC Wainwright & Co. | Buy | 25 авг 2021 г. | |
| Benchmark | Speculative Buy | 16 июн 2020 г. | |
| Ladenburg Thalmann | Buy | 27 апр 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lieber Jonathan I | A | 2940 | 1440 | 03 янв 2023 г. |
| McCreedy Bruce J Jr. | A | 1788 | 1440 | 03 янв 2023 г. |
| Lammers Paul | A | 1718 | 1440 | 03 янв 2023 г. |
| HANISH ARNOLD C | A | 1440 | 1440 | 03 янв 2023 г. |
| McVicar William K. | A | 1788 | 1440 | 03 янв 2023 г. |
| Burleson Tess | A | 2722 | 1440 | 03 янв 2023 г. |
| Arthur David J. | A | 33719 | 20000 | 03 янв 2023 г. |
| Rosenblum Mark J | A | 15419 | 8000 | 03 янв 2023 г. |
| Rosenblum Mark J | A | 13245 | 7314 | 03 ноя 2022 г. |
| Arthur David J. | A | 21026 | 10000 | 03 ноя 2022 г. |
Новостная лента
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood
Market Watch
09 мая 2023 г. в 08:17
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation.
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
GlobeNewsWire
04 апр 2023 г. в 16:02
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
GlobeNewsWire
19 янв 2023 г. в 08:30
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
GlobeNewsWire
19 окт 2022 г. в 08:30
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius' director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban's presentation, titled “Development of SP-3164, a Cereblon-Binding Molecular Glue,” will be delivered at 5:30 p.m. local time on October 26th.
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
GlobeNewsWire
20 сент 2022 г. в 12:00
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that management will present at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29th in New York City at the Sofitel Hotel. David Arthur, chief executive officer, will deliver a corporate presentation and participate in a “fireside chat” at 10:30 a.m. Eastern time. In addition to Mr. Arthur, other management team members will be available for one-on-one meetings. Please contact Ladenburg Thalmann to schedule a meeting.